This inventor holds 1 USPTO granted patent. Top assignee: Oy Juvantia Pharma Ltd.. Active years: 2004.
Company Filing History:
Years Active: 2004
Title: Amir Snapir: Innovator in Genetic Research
Introduction
Amir Snapir is a notable inventor based in Turku, Finland. He has made significant contributions to the field of genetic research, particularly in the development of DNA molecules that have potential therapeutic applications.
Latest Patents
Amir Snapir holds a patent for a DNA molecule encoding a variant α2B-adrenoceptor protein and its uses. This invention relates to a DNA sequence that comprises a nucleotide sequence encoding a variant α-adrenoceptor protein. It also includes a method for screening subjects to determine if they are carriers of a variant gene that encodes this protein. Furthermore, the invention outlines a method for treating mammals suffering from vascular contraction of coronary arteries by administering a selective α-adrenoceptor antagonist. The patent also covers transgenic animals that contain a human DNA molecule encoding the human α-adrenoceptor protein or the variant α-adrenoceptor protein. He has 1 patent to his name.
Career Highlights
Amir Snapir is associated with Oy Juvantia Pharma Ltd., where he continues to work on innovative solutions in the pharmaceutical industry. His research focuses on the implications of genetic variations in medical treatments.
Collaborations
Amir collaborates with talented professionals in his field, including Paula Heinonen and Pia Alhopuro. Their combined expertise enhances the research and development efforts at Oy Juvantia Pharma Ltd.
Conclusion
Amir Snapir's work in genetic research and his patented innovations demonstrate his commitment to advancing medical science. His contributions have the potential to impact the treatment of vascular conditions significantly.